{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:11:42Z","timestamp":1785417102728,"version":"3.56.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jcf.2024.01.006","type":"journal-article","created":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T09:03:40Z","timestamp":1706346220000},"page":"563-565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Subtherapeutic triazole concentrations as result of a drug-drug interaction with lumacaftor\/ivacaftor"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2197-3405","authenticated-orcid":false,"given":"T.J.L.","family":"Smeets","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"van der Sijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.M.","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.J.","family":"Ruijgrok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4452-8443","authenticated-orcid":false,"given":"B.C.M.","family":"de Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.01.006_bib0001","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11046-017-0184-y","article-title":"Fungal pathogens in cf airways: leave or treat?","volume":"183","author":"Singh","year":"2018","journal-title":"Mycopathologia"},{"key":"10.1016\/j.jcf.2024.01.006_bib0002","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/mmy\/myw035","article-title":"Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center","volume":"54","author":"Ziesing","year":"2016","journal-title":"Med Mycol"},{"key":"10.1016\/j.jcf.2024.01.006_bib0003","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients","volume":"45","author":"Bellmann","year":"2017","journal-title":"Infection"},{"key":"10.1016\/j.jcf.2024.01.006_bib0004","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13318-018-0513-7","article-title":"Clinical pharmacokinetics of second-generation triazoles for the treatment of invasive aspergillosis and candidiasis","volume":"44","author":"Jovi\u0107","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jcf.2024.01.006_bib0005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jac\/dkw349","article-title":"Voriconazole metabolism is influenced by severe inflammation: a prospective study","volume":"72","author":"Veringa","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcf.2024.01.006_bib0006","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1002\/ppul.23505","article-title":"Therapeutic challenges posed by critical drug-drug interactions in cystic fibrosis","volume":"51","author":"Jordan","year":"2016","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.01.006_bib0007","unstructured":"Summary of product characteristics orkambi\u00ae. 2024 https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/orkambi-epar-product-information_nl.pdf."},{"key":"10.1016\/j.jcf.2024.01.006_bib0008","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ccr3.2053","article-title":"Lumacaftor\/ivacaftor initiation in two liver transplantation patients under tacrolimus and antifungal azoles","volume":"7","author":"Chouchane","year":"2019","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jcf.2024.01.006_bib0009","unstructured":"Summary of product characteristics Kaftrio\u00ae. 2024 https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kaftrio-epar-product-information_nl.pdf."},{"key":"10.1016\/j.jcf.2024.01.006_bib0010","unstructured":"Summary of product characteristics Symkevi\u00ae. 2024 https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/symkevi-epar-product-information_nl.pdf."},{"key":"10.1016\/j.jcf.2024.01.006_bib0011","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2022.10.002","article-title":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","volume":"22","author":"Southern","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.01.006_bib0012","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1002\/ppul.25080","article-title":"Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations:\u00a0 II. Therapies for allergic bronchopulmonary aspergillosis","volume":"55","author":"Epps","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.01.006_bib0013","article-title":"Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","volume":"9","author":"Francis","year":"2022","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:31:55Z","timestamp":1777649515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1569199324000080"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.01.006","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subtherapeutic triazole concentrations as result of a drug-drug interaction with lumacaftor\/ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}